NCT07246330
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
- Locations
-
Not specified
Clinical trial condition
Esophageal Neoplasms
Explore clinical trials studying Esophageal Neoplasms. Study availability and eligibility vary by location and protocol.
304 public trials
108 recruiting studies
Esophageal Neoplasms trial results
Not Yet Recruiting
A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.
NCT07203898
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
- Locations
-
Not specified
Not Yet Recruiting
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
NCT07152535
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
- Locations
-
Not specified
NCT07128693
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
- Locations
-
Not specified
Not Yet Recruiting
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
NCT07067450
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
- Locations
-
Not specified
Not Yet Recruiting
QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
NCT07049185
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
- Locations
-
Not specified
Not Yet Recruiting
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
NCT06861894
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
- Locations
-
- Shanghai Chest Hospital Shanghai, China
Not Yet Recruiting
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
NCT06903871
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +14 more
- Locations
-
- Hebei Medical University Fourth Hospital Shijiazhuang, Hebei, China
Not Yet Recruiting
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
NCT06861777
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
- Locations
-
- Cancer Hospital, Chinese Academy of Medical Sciences Beijing, China
Not Yet Recruiting
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
NCT06746961
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
- Locations
-
Not specified